Skip to content
GLP-1 Savers
Menu

Head-to-head · Value Score

CoreAge Rx vs 9amHealth

Two GLP-1 deals, scored on the same six factors. CoreAge Rx lands a Value Score of 93, 9amHealth a 61. Here's who gives you the honest lower price — and where each one bites back.

★ Better value

CoreAge Rx

#1 · Grade A+ · Best Value

Est. first month

$149/mo

Save ~89% vs brand-name
Get this deal Full CoreAge Rx review →
VS

9amHealth

#354 · Grade C · Watch List

Est. first month

From $149/mo (plus a separate fee, brand-name)

Get this deal Full 9amHealth review →

The verdict

Better value: CoreAge Rx

CoreAge Rx takes it on Value Score, 93 to 61 an est. $149/mo first month, with no teaser step-up baked in. 9amHealth isn't out of it: Shoppers who want insured patients wanting branded GLP-1s within a full cardiometabolic care program.

CoreAge Rx is also our overall #1 pick across the whole deals board — a flat, all-in price on both molecules in all 50 states. That's why it wins here on the score, not just this matchup.

Deal-by-deal

The numbers that decide it. Green ✓ marks the stronger side on each line.

DealCoreAge Rx9amHealth
Value Score93 (A+)61 (C)
Est. first month$149/moFrom $149/mo (plus a separate fee, brand-name)
Save vs brand-name~89%
Semaglutide$149/moFrom $149/mo (plus a separate fee, brand-name)
Tirzepatide$349/moNot disclosed
Both moleculesYesNo
PricingFlat — no step-upWatch
CoverageAll 50 statesCoverage not published

Factor by factor

The six factors behind each Value Score. The orange bar marks the stronger side. See the methodology.

88
Lowest Real Price
82
CoreAge Rx: 88. 9amHealth: 82.
98
No Teaser-Rate Bait
26
CoreAge Rx: 98. 9amHealth: 26.
98
Nationwide Availability
45
CoreAge Rx: 98. 9amHealth: 45.
95
Both Molecules
62
CoreAge Rx: 95. 9amHealth: 62.
95
Easy Cancellation
58
CoreAge Rx: 95. 9amHealth: 58.
84
Reputation
80
CoreAge Rx: 84. 9amHealth: 80.

CoreAge Rx

The honest lowest price: both molecules at one flat, all-in monthly rate that never steps up after month one.

Why it's a deal

  • Flat, all-in monthly price with no intro-rate step-ups after month one
  • Both compounded semaglutide and tirzepatide on one account
  • Available in all 50 states
  • Straightforward, low-friction cancellation — no lock-in

The fine print

  • Not the rock-bottom sticker — a couple of teaser tiers advertise lower month-one rates
  • No FDA-approved brand-name option (compounded only)
  • Does not yet publicly name its 503A/B pharmacy partner

9amHealth

9amHealth (join9am.com) is a cardiometabolic telehealth platform offering whole-body care including weight management with FDA-approved branded GLP-1 medications such as Wegovy, Zepbound, and Saxenda, plus…

Why it's a deal

  • Prescribes FDA-approved branded GLP-1s (Wegovy, Zepbound, Saxenda)
  • $149/month membership or free when covered by insurance
  • Membership includes specialists, labs, devices, and medications
  • Board-certified obesity specialists (DABOM), endocrinologists, dietitians, PharmDs
  • Helps navigate insurance approvals; employer and state-plan partnerships

The fine print

  • Medication coverage and GLP-1 access depend on insurance and BMI criteria
  • State availability not enumerated on the public site
  • Branded GLP-1s can be costly without insurance coverage
  • Pricing for medications not transparently listed
Get the CoreAge Rx deal Get the 9amHealth deal

Assume any provider we list may compensate us — we may earn a commission, at no cost to you. It never changes a Value Score.

Neither one the right fit? Every program that outscores CoreAge Rx is ranked on the CoreAge Rx alternatives board, and the same list for the other side is on alternatives to 9amHealth.

More head-to-heads

← All comparisons

Prices, states and verification reflect each program's public disclosures at last check; the Value Score is our editorial judgment per the methodology. “Save vs brand-name” compares the lowest disclosed monthly price against a ~$1,349/mo brand-name cash reference. Prices change — confirm on each provider's site. Not medical advice; see our disclosure.